Cardiol Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Cardiol Therapeutics Class
CRDL Stock  USD 1.06  0.07  7.07%   
Cardiol Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Cardiol Therapeutics' valuation are provided below:
Gross Profit
78.8 K
Market Capitalization
111.1 M
Enterprise Value Revenue
178.8107
Earnings Share
(0.30)
There are over one hundred nineteen available fundamental signals for Cardiol Therapeutics Class, which can be analyzed over time and compared to other ratios. We recommend to validate Cardiol Therapeutics' prevailing fundamental drivers against the all of the trends between 2010 and 2026. The value of Market Cap is estimated to slide to about 73.2 M. The Enterprise Value is projected to slide to about 67.1 M
Check Cardiol Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cardiol Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 1.4 M, Interest Income of 707.2 K or Depreciation And Amortization of 155 K, as well as many indicators such as Price To Sales Ratio of 1 K, Dividend Yield of 0.0 or PTB Ratio of 8.31. Cardiol financial statements analysis is a perfect complement when working with Cardiol Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Cardiol Stock
Check out the analysis of Cardiol Therapeutics Correlation against competitors.

Cardiol Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets36 M36.6 M21 M
Slightly volatile
Short and Long Term Debt Total131.1 K142.7 K171.5 K
Slightly volatile
Other Current Liabilities8.4 M8 M2 M
Slightly volatile
Total Current Liabilities5.4 M8.1 M3.2 M
Slightly volatile
Total Stockholder Equity30.4 M28.4 M17.6 M
Slightly volatile
Net Tangible Assets32.7 M59.7 M22.9 M
Slightly volatile
Property Plant And Equipment Net304.6 K224.9 K169.2 K
Slightly volatile
Accounts Payable4 M8 M2.5 M
Slightly volatile
Cash32.1 M35.2 M18.6 M
Slightly volatile
Non Current Assets Total167.2 K176 K639.9 K
Slightly volatile
Long Term Debt252.6 K309.6 K233.4 K
Slightly volatile
Cash And Short Term Investments32.1 M35.2 M18.7 M
Slightly volatile
Net Receivables277.2 K325.5 K240.4 K
Slightly volatile
Common Stock Shares Outstanding47.3 M82.3 M37.2 M
Slightly volatile
Liabilities And Stockholders Equity36 M36.6 M21 M
Slightly volatile
Non Current Liabilities Total107.8 K113 K154.6 K
Slightly volatile
Other Current Assets1.2 M835.5 K629.9 K
Slightly volatile
Total Liabilities5.6 M8.2 M3.4 M
Slightly volatile
Net Invested Capital32.3 M28.4 M18.6 M
Slightly volatile
Total Current Assets35.2 M36.4 M20.3 M
Slightly volatile
Accumulated Other Comprehensive Income2.9 M4 M1.8 M
Slightly volatile
Net Working Capital31.6 M28.4 M18 M
Slightly volatile
Intangible Assets362.1 K189.3 K526.4 K
Slightly volatile
Common Stock216.5 M206.2 M68.5 M
Slightly volatile
Property Plant Equipment322.7 K340.1 K185.1 K
Slightly volatile
Capital Stock117.3 M206.2 M80.2 M
Slightly volatile
Short Term Investments46.7 K55.7 K59.2 K
Slightly volatile
Capital Lease Obligations116.1 K142.7 K167.4 K
Slightly volatile
Property Plant And Equipment Gross884.7 K1.1 M751 K
Slightly volatile
Short Term Debt31.1 K29.7 K44 K
Slightly volatile
Other Assets0.80.90.9824
Slightly volatile

Cardiol Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income707.2 K1.4 M427.4 K
Slightly volatile
Depreciation And Amortization155 K186.4 K108.3 K
Slightly volatile
Selling General Administrative16.4 M30.2 M10.2 M
Slightly volatile
Other Operating Expenses48.6 M46.3 M15.7 M
Slightly volatile
Research Development8.3 M16.1 M5.2 M
Slightly volatile
Cost Of Revenue151.6 K215.5 K111.3 K
Slightly volatile
Total Operating Expenses48.6 M46.3 M15.6 M
Slightly volatile
Reconciled Depreciation217 K429.1 K152.8 K
Slightly volatile
Selling And Marketing Expenses12.2 M13.8 M15 M
Slightly volatile

Cardiol Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation17.2 M16.4 M4.3 M
Slightly volatile
Depreciation218.2 K429.1 K153.4 K
Slightly volatile
Capital Expenditures18.2 K19.2 K54.3 K
Very volatile
End Period Cash Flow34.2 M35.2 M19.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1 K1.2 K1.3 K
Slightly volatile
PTB Ratio8.316.1618.0039
Slightly volatile
Days Sales Outstanding1.5 K1.7 K1.9 K
Slightly volatile
Book Value Per Share0.380.40.4488
Slightly volatile
Stock Based Compensation To Revenue86.3297.11106
Slightly volatile
Capex To Depreciation0.06230.06560.4767
Pretty Stable
PB Ratio8.316.1618.0039
Slightly volatile
EV To Sales172193211
Slightly volatile
Inventory Turnover12.0711.55.1593
Slightly volatile
Days Of Inventory On Hand31.2132.8613.6 K
Slightly volatile
Payables Turnover0.120.06150.1677
Slightly volatile
Sales General And Administrative To Revenue283319348
Slightly volatile
Average Inventory2.8 M3.4 M3.4 M
Slightly volatile
Research And Ddevelopement To Revenue110124136
Slightly volatile
Capex To Revenue0.130.150.1612
Slightly volatile
Cash Per Share0.580.380.44
Slightly volatile
Days Payables Outstanding6.1 K6.1 K5.9 K
Slightly volatile
Income Quality0.690.790.7044
Slightly volatile
Intangibles To Total Assets0.00630.00660.112
Slightly volatile
Net Debt To EBITDA0.980.751.2588
Slightly volatile
Current Ratio10.275.211.0945
Slightly volatile
Tangible Book Value Per Share0.380.40.4284
Slightly volatile
Receivables Turnover0.150.170.1895
Slightly volatile
Shareholders Equity Per Share0.380.40.4488
Slightly volatile
Debt To Equity0.0070.00740.0352
Slightly volatile
Capex Per Share3.0E-43.0E-40.0018
Very volatile
Graham Net Net0.510.30.388
Slightly volatile
Average Receivables467.4 K368.9 K506.5 K
Slightly volatile
Revenue Per Share0.00150.00160.0018
Slightly volatile
Interest Debt Per Share0.00240.00250.0103
Slightly volatile
Debt To Assets0.00540.00570.0311
Slightly volatile
Operating Cycle2.1 K2.2 K14.3 K
Slightly volatile
Price Book Value Ratio8.316.1618.0039
Slightly volatile
Days Of Payables Outstanding6.1 K6.1 K5.9 K
Slightly volatile
Ebt Per Ebit1.141.051.0479
Pretty Stable
Company Equity Multiplier0.941.161.1423
Pretty Stable
Long Term Debt To Capitalization0.00610.00640.0328
Slightly volatile
Total Debt To Capitalization0.0070.00730.0332
Slightly volatile
Debt Equity Ratio0.0070.00740.0352
Slightly volatile
Quick Ratio9.645.210.7874
Slightly volatile
Net Income Per E B T0.410.430.8211
Slightly volatile
Cash Ratio8.075.029.713
Slightly volatile
Days Of Inventory Outstanding31.2132.8613.6 K
Slightly volatile
Days Of Sales Outstanding1.5 K1.7 K1.9 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.0288
Slightly volatile
Price To Book Ratio8.316.1618.0039
Slightly volatile
Fixed Asset Turnover0.180.20.2173
Slightly volatile
Debt Ratio0.00540.00570.0311
Slightly volatile
Price Sales Ratio1 K1.2 K1.3 K
Slightly volatile
Asset Turnover7.0E-48.0E-49.0E-4
Slightly volatile
Price Fair Value8.316.1618.0039
Slightly volatile

Cardiol Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap73.2 M119.2 M95.6 M
Pretty Stable

Cardiol Fundamental Market Drivers

Cardiol Upcoming Events

26th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cardiol Therapeutics Financial Statements

Cardiol Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Cardiol Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-6.9 M-7.2 M
Cost Of Revenue215.5 K151.6 K
Stock Based Compensation To Revenue 97.11  86.32 
Sales General And Administrative To Revenue 318.51  283.12 
Research And Ddevelopement To Revenue 124.22  110.42 
Capex To Revenue 0.15  0.13 
Ebit Per Revenue(519.63)(545.61)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Cardiol Therapeutics is a strong investment it is important to analyze Cardiol Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiol Therapeutics' future performance. For an informed investment choice regarding Cardiol Stock, refer to the following important reports:
How To Invest In Cardiol
Details
Is Cardiol Stock a good investment?
Details
What is Cardiol Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Cardiol Therapeutics Correlation against competitors.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. Projected growth potential of Cardiol fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cardiol Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(0.30)
Return On Assets
(1.49)
Return On Equity
(3.48)
Understanding Cardiol Therapeutics requires distinguishing between market price and book value, where the latter reflects Cardiol's accounting equity. The concept of intrinsic value - what Cardiol Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Cardiol Therapeutics' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Cardiol Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cardiol Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Cardiol Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY